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LETTER TO THE EDITOR Open Access
Therapeutic activity of two xanthones in a
xenograft murine model of human chronic
lymphocytic leukemia
Séverine Loisel1, Karine Le Ster2, Michèle Meyer3, Christian Berthou1,2, Pierre Youinou1,2, Jean-Pierre Kolb4,5,6,
Christian Billard4,5,6*
Abstract
Background: We previously reported that allanxanthone C and macluraxanthone, two xanthones purified from
Guttiferae trees, display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic
lymphocytic leukemia (CLL) and leukemia B cell lines.
Results: Here, we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of
human CLL, developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the
animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant
prolongation of their survival as compared to control animals injected with the solvent alone (p = 0.0006 and p =
0.0141, respectively). The same treatment of mice which were not xenografted induced no mortality.
Conclusion: These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones,
and confirm their potential interest for CLL therapy.
To the Editor,
Despite recent therapeutic advances with the combina-
tion of purine analogs, alkylating agents and monoclonal
antibodies, chronic lymphocytic leukemia (CLL) remains
an incurable disease [1-3]. It is characterized by the clo-
nal expansion of a population of CD5+ B lymphocytes
and by the accumulation in the blood of leukemic cells
that are quiescent but defective in their apoptotic pro-
gram [2,4]. Thus, CLL is a disease of proliferation as well
as accumulation. Treatments targeting both dividing and
apoptosis-deficient quiescent cells might therefore
improve the CLL patients’ outcome [2-4]. A number of
plant-derived compounds were found to exhibit in vitro
capacities to either inhibit leukemic cell growth or induce
apoptosis or both, but their clinical use was hampered by
the lack of in vivo studies on animal models of CLL.
However, some murine models recapitulating the human
CLL disease were described lately, such as the TCL1
transgenic mouse model developing a CD5+ B cell
lymphoproliferative disease typical of aggressive CLL [5].
We previously showed that several xanthones purified
from african trees of the Guttiferae family display both
antiproliferative and proapoptotic properties in cell lines
derived from CLL and hairy cell leukemia (HCL), another
chronic B-cell leukemia [6]. In addition, these com-
pounds can induce the apoptosis of primary CLL cells
in vitro through different mechanisms [6]. It seemed
therefore crucial to determine whether some xanthones
are capable of in vivo therapeutic effects in an animal
model of CLL.
We selected two of the xanthones which were purified
and characterized in our previous study [6] on the basis
of their in vitro activities in CLL cells and their hardly
detectable toxicity in B lymphocytes from healthy
donors: (i) allanxanthone C, a xanthenedione that we
have identified as acting by caspase activation, possibly
through a mechanism involving inhibition of the NO
pathway [4]; and (ii) macluraxanthone, originaly found
to inhibit the growth of solid tumor cell lines [7] and
moreover, capable of triggering the mitochondrial path-
way of apoptosis in CLL cells [6]. Taking advantage of
our previous data [8], we developed a xenograft mouse
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model by engrafting CD5-transfected human JOK-1 cells
into SCID mice (Le Ster et al, submitted). Actually, it
was demonstrated that transplantation of this cell line
JOK-1 into SCID mice led to the establishment of a
CLL model, allowing the evaluation of the antileukemic
efficacy of fludarabine phosphate [9]. Furthermore, we
reported that CD5 plays a prominent role in the control
of CLL cell apoptosis through its distribution in lipid
rafts and its interaction with the B-cell receptor [10].
Whereas CD5 is generally lost in long-term cultures of
CLL cell lines, JOK-1/5.3 cells derived by stable trans-
fection of the human CD5 gene into JOK-1 cells display
a phenotype somewhat close to that of primary leukemic
cells. The xenografted mice that we obtained developed
a leukemia resembling the CLL type as defined by the
French-American-British criteria.
We first verified that the xanthones were active on the
JOK-1/5.3 cells used for engrafting the mice. Treatment
with either allanxanthone C or macluraxanthone for 18 h
resulted in a concentration-dependent inhibition of cell
growth, peaking at respectively 40% and 70% with 40 μM
(estimated by 3H-thymidine uptake), in accordance with
our previous data on CLL and HCL cell lines [6]. Both
compounds induced the accumulation in the G0/G1
phase of the cell cycle as compared to untreated cells
(P < 0.05) and decreased the percentages of cells in S and
G2/M phases (evaluated by propidium iodide incorpora-
tion using flow cytometry and Multicycle AV program).
Two other xanthones, 1,7-dihydroxanthone and a-
mangostin which were inactive in our previous study [6]
were used as negative controls. The proapoptotic capaci-
ties of allanxanthone C and macluraxanthone were also
checked in JOK-1/5.3 cells by stimulation of phosphati-
dylserine externalization (quantified by annexin V-FITC
binding), although these cells turned out to be less sensi-
tive than primary CLL cells.
For the in vivo experiments, randomised groups of
SCID CB-17 mice were inoculated with 107 JOK-1/5.3
cells (day 0). Xenografted mice were treated at days 3 to
7 with five daily injections of either allanxanthone C or
macluraxanthone (5 mg/kg) or solvent alone as untreated
control. The three groups of mice were then monitored
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Figure 1 Xanthones prolong the survival of SCID mice xenografted with human JOK1/5.3 cells. Three randomized groups of 6-8 weeks
old female CB-17 SCID mice (5/group) were inoculated intravenously with 10 × 106 JOK-1/5.3 cells (in 0.1 ml PBS) on day 0 and treated with 5
daily iv injections (0.2 ml in saline) on days 3 to 7 (arrows) of 5 mg/kg of allanxanthone C (black triangle) or macluraxanthone in DMSO (white
square) or of solvent (DMSO in saline) alone (black losange). The three groups of xenografted mice were then checked daily for survival and the
cumulative survival data were analyzed according to the Kaplan-Meier’s curves. For details, see the text.
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daily and the survival was estimated according to the
Kaplan-Meier’s method (Figure 1). Mean survival times ±
SE were 25.6 ± 0.6 days and 26.0 ± 1.7 days for respec-
tively allanxanthone C and macluraxanthone-treated
mice versus 20.2 ± 0.8 days for untreated control mice.
These increases in survival (27% and 29% respectively)
were significant with P values of 0.0006 for allanxanthone
C group and of 0.0141 for macluraxanthone group as
compared to control group (according to the Student’s
unpaired t-test). No significant difference was detected
between the two groups of xanthone-treated mice (P =
0.83). These results show that treatments of the xeno-
grafted mice with allanxanthone C and macluraxanthone
resulted in a prolongation of their lifespan.
To check a toxicity of the xanthones, two groups of
5 mice which were not inoculated with JOK-1/5.3 cells
were treated with either allanxanthone C or maclurax-
anthone according to the same protocol as before. No
lethality was observed in these two groups of animals,
suggesting an absence of toxicity of the xanthones per se
under the treatment protocol used. This also favors that
the deaths observed in the JOK-1/5.3-grafted mice were
due to the presence of the leukemic cells, and that treat-
ments with the xanthones were able to delay signifi-
cantly these lethal effects.
In conclusion, results presented in this letter show for
the first time that allanxanthone C and maclurax-
anthone purified from Guttiferaes are capable of in vivo
antileukemic effects in a xenograft murine model of
human CLL. These therapeutic activities of the natural
compounds, of similar extent, occur without apparent
toxicity. Although the comparison with known che-
motherapeutic agents has to be performed, our data
provide further confirmation that these xanthones might
be used as new agents for the therapy of CLL and possi-
bly allied chronic B cell malignancies. Experiments
examining the effects of increasing doses and time of
treatment as well as different schedules of administra-
tion are in progress in order to improve the therapeutic
efficacy of the two xanthones. Studies of their exact
mechanisms of action in primary CLL patients’ cells are
also considered in order to define therapeutic targets.
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